Literature DB >> 3691613

The disposition and metabolism of (+)-cyanidanol-3 in patients with alcoholic cirrhosis.

M V Smillie1, L A Griffiths, P J Male, M M Wermeille.   

Abstract

The effect of alcoholic cirrhosis of the liver on the disposition and metabolism of (+)-cyanidanol-3 has been studied in three patients. Following oral intake of U-14C-(+)-cyanidanol-3 2 g, the unchanged drug was detected in plasma between 0.5 and 24 h after dosing and the metabolites, measured only as 14C-levels, were still detectable at 120 h. A mean of 55% of the dose was excreted in the urine, in which the major metabolites were the glucuronic and sulphuric acid conjugates of (+)-cyanidanol-3 and 3'-O-methyl-(+)-cyanidanol-3, although one patient excreted a larger proportion as non-conjugated metabolites. The pattern of metabolism in the patients did not differ significantly from that in control subjects, suggesting that the drug is handled by the cirrhotic liver in a similar manner to the normal liver.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3691613     DOI: 10.1007/bf00637558

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  13 in total

1.  Studies on sulphatases. 4. Arylsulphatase and beta-glucuronidase concentrates from limpets.

Authors:  K S DODGSON; B SPENCER
Journal:  Biochem J       Date:  1953-09       Impact factor: 3.857

2.  Comparison of some pharmacokinetic parameters of (+)-cyanidanol-3 obtained with specific and non-specific analytical methods.

Authors:  L Balant; B Burki; M Wermeille; G Golden
Journal:  Arzneimittelforschung       Date:  1979

3.  Drugs as indicators of hepatic function.

Authors:  R A Branch
Journal:  Hepatology       Date:  1982 Jan-Feb       Impact factor: 17.425

4.  Metabolism and excretion of the liver-protective agent (+)-catechin in experimental hepatitis.

Authors:  I C Shaw; A M Hackett; L A Griffiths
Journal:  Xenobiotica       Date:  1982-07       Impact factor: 1.908

5.  Cianidanol therapy for HBe-antigen-positive chronic hepatitis: a multicentre, double-blind study.

Authors:  H Suzuki; S Yamamoto; C Hirayama; T Takino; K Fujisawa; T Oda
Journal:  Liver       Date:  1986-02

6.  The metabolism and excretion of (+)-[14C]cyanidanol-3 in man following oral administration.

Authors:  A M Hackett; L A Griffiths; A Broillet; M Wermeille
Journal:  Xenobiotica       Date:  1983-05       Impact factor: 1.908

7.  Determinants of drug disposition in patients with cirrhosis.

Authors:  P M Huet; J P Villeneuve
Journal:  Hepatology       Date:  1983 Nov-Dec       Impact factor: 17.425

8.  3'-O-methyl-(+)-catechin glucuronide and 3'-O-methyl-(+)-catechin sulphate: new urinary metabolites of (+)-catechin in the rat and the marmoset.

Authors:  A M Hackett; I C Shaw; L A Griffiths
Journal:  Experientia       Date:  1982-05-15

9.  Treatment of acute viral hepatitis with (+)-cyanidanol-3.

Authors:  A L Blum; P Berthet; W Doelle; H Goebell; K Kortüm; S Pelloni; P Peter; H Poulsen; G Strohmeyer; N Tygstrup
Journal:  Lancet       Date:  1977-12-03       Impact factor: 79.321

10.  Studies on flavonoid metabolism. Metabolism of (+)-[14C] catechin in the rat and guinea pig.

Authors:  N P Das; L A Griffiths
Journal:  Biochem J       Date:  1969-12       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.